Merck Animal Health Completes Acquisition of Elanco’s Aqua Business - Merck.com (2024)

July 9, 2024 12:00 am ET

Acquisition delivers industry-leading portfolio, scientific and research capabilities, for enhanced customer benefits

RAHWAY, N.J., July 9, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announcedthe completion of its acquisition of the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN). The completion of this acquisition bolsters Merck Animal Health’s position in the aqua industry with a comprehensive approach to promote fish health, welfare and sustainability in aquaculture, conservation, and fisheries.

“With the completion of this acquisition, we are well positioned within the aquaculture industry with a robust and comprehensive portfolio across warm water, cold water, vaccines, anti-parasitic treatments, water supplements and nutrition,” said Rick DeLuca, president, Merck Animal Health. “We are excited to welcome our new colleagues to Merck Animal Health and we look forward to working together, driven by our common purpose of the Science of Healthier Animals®.”

As a result of the acquisition, Merck Animal Health now owns innovative products such as CLYNAV®, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease and IMVIXA®, an anti-parasitic sea lice treatment and water treatment products for warm water production, complementing Merck Animal Health’s vaccine portfolio.

The increasing use of medicines and vaccines, nutritionals and supplements for aquatic species is driven by the growing demand for protein and food safety, ensuring a supply of quality food and protecting public health.

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to TheScience of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Merck Animal Health Completes Acquisition of Elanco’s Aqua Business - Merck.com (1)

Merck Investor Contacts:
Peter Dannenbaum

(732) 594-1579
Merck Media Contacts:

Robert Josephson
(203) 914- 2372

Kim Gorode
(973) 255-8904

Source: Merck & Co., Inc.

Merck Animal Health Completes Acquisition of Elanco’s Aqua Business - Merck.com (2024)

FAQs

Did Merck animal health buy Elanco's aqua business? ›

RAHWAY, N.J., July 9, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN).

Is Merck animal health part of Merck? ›

Intervet/Schering-Plough Animal Health becomes the animal health division of Merck, including HomeAgain®, a leader in microchip and pet recovery services.

What is Merck animal health Vision Statement? ›

Merck Animal Health is our company's global animal health business dedicated to preserving and improving the health, well-being and performance of both livestock and companion animals and the people who care for them.

Did Merck buy Elanco's aqua business for $1.3 B in cash? ›

WASHINGTON—Covington advised Merck in its definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in ...

Who did Zoetis buy out? ›

Zoetis Inc. today announced that it has completed the purchase of the animal health assets of Abbott for a purchase price of $255 million, having fulfilled all closing requirements.

Who is Merck owned by? ›

The Merck Group includes around 250 companies in 180 countries; the current main parent company of the group, since 1995, is named Merck KGaA, and is itself mainly owned by the former main parent company, E. Merck oHG, which now operates as a holding company. The American pharmaceutical company Merck & Co.

What is Merck's biggest product? ›

Merck's top product Keytruda

Over the last years, Keytruda was ranked first among the top cancer drugs worldwide based on revenue.

What is the Elanco animal health strategy? ›

For our customers, we promise to be your advocate and continually earn your trust, improving the health of animals, and creating value through innovative products, expertise and service. We find ways to add value with every customer engagement, addressing what matters most, and constantly raising the bar.

Who bought Aqua? ›

Merck Animal Health, a division of Rahway-based Merck & Co., on Monday announced that it has signed an agreement to acquire the aqua business of Elanco Animal Health Inc. for $1.3 billion.

Who bought Novartis Animal Health? ›

Eli Lilly and Co. announced April 22 an agreement to acquire Novartis Animal Health for $5.4 billion to strengthen and diversify Lilly's animal health business, Elanco. On completion of the acquisition, Elanco will be the second largest animal health company in terms of global revenue, after Zoetis.

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Dong Thiel

Last Updated:

Views: 6020

Rating: 4.9 / 5 (59 voted)

Reviews: 82% of readers found this page helpful

Author information

Name: Dong Thiel

Birthday: 2001-07-14

Address: 2865 Kasha Unions, West Corrinne, AK 05708-1071

Phone: +3512198379449

Job: Design Planner

Hobby: Graffiti, Foreign language learning, Gambling, Metalworking, Rowing, Sculling, Sewing

Introduction: My name is Dong Thiel, I am a brainy, happy, tasty, lively, splendid, talented, cooperative person who loves writing and wants to share my knowledge and understanding with you.